Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECEPT: CEP-1347 in Early Parkinson's Disease
NCT00040404Phase 3Terminated
- Sponsor
- Cephalon, Inc.
- Start
- Mar 2002
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of CEP1347 in Parkinson's disease (PD), sponsored by Cephalon, Inc.. Started Mar 2002; status: terminated.
02
Drugs
CEP1347
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00040404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040404.